Screener
Lexicon Pharmaceuticals LXRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| (Increase) decrease in prepaid expenses and other current assets | (128) | 806 |
| Decrease in other long-term assets | 397 | 376 |
| Decrease in accounts payable and other liabilities | (1,996) | (10,569) |
| Net cash used in operating activities | (23,922) | (26,785) |
| Cash flows from investing activities: | ||
| Purchases of investments | (163,221) | (90,943) |
| Maturities of investments | 76,497 | 147,008 |
| Net cash (used in) provided by investing activities | (86,724) | 56,065 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's operating cash flow?
- Lexicon Pharmaceuticals (LXRX) reported operating cash flow of -$9.19M in Q2 2026.
- What is the long-term trend for Lexicon Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2024), Lexicon Pharmaceuticals's operating cash flow has grown at a 27.1% compound annual growth rate (CAGR), from -$87.02M to -$178.78M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Lexicon Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude